Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cytidine 5' Monophosphate→

Cytidine 5' Monophosphate Environmental Risk Assessment (ERA)

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
Not available in the source profile
Molecular formula
Not available in the source profile
Molecular weight
Not available in the source profile
View request basketPrefer email? info@regusight.com
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Project-specific scope

Adapted to the product and intended market.

The product, route, maximum daily dose, use pattern, target market and available evidence determine the applicable ERA pathway and documentation needs.

  • Product and intended-market review.
  • Assessment pathway and data-gap review.
  • Market-specific calculation and documentation considerations.
  • Structured final report within the agreed scope.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.